Indivior ( (INDV) ) just unveiled an update.
Indivior PLC reported its first-quarter 2025 financial results, with total net revenue of $266 million, a 6% decline from the previous year, primarily due to increased generic competition for SUBOXONE Film and the discontinuation of PERSERIS. Despite these challenges, SUBLOCADE’s net revenue remained consistent with guidance, and the company is on track to achieve over $100 million in annual operating expense savings for FY 2025. The FDA-approved label changes for SUBLOCADE are expected to enhance patient and physician experiences, potentially driving growth in the second half of the year. The company completed a $100 million share repurchase program and maintained its FY 2025 guidance, highlighting its strategic focus on opioid use disorder treatments.
More about Indivior
Indivior PLC operates in the pharmaceutical industry, focusing on addiction treatment products. Its primary products include SUBLOCADE, an extended-release buprenorphine injection, and SUBOXONE Film, a medication-assisted treatment for opioid addiction. The company is committed to addressing the opioid epidemic and expanding access to treatment.
YTD Price Performance: -32.13%
Average Trading Volume: 366,068
Technical Sentiment Signal: Buy
Current Market Cap: £827.6M
For a thorough assessment of INDV stock, go to TipRanks’ Stock Analysis page.